Related references
Note: Only part of the references are listed.Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
Francesco Buccisano et al.
BLOOD (2012)
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
John A. Liu Yin et al.
BLOOD (2012)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia
Francesco Buccisano et al.
BLOOD (2010)
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Jeffrey E. Rubnitz et al.
LANCET ONCOLOGY (2010)
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes
Yachiyo Kuwatsuka et al.
BLOOD (2009)
HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission:: Collaborative study between the German AML intergroup and CIBMTR
Richard F. Schlenk et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): A retrospective study from the European Cooperative Group for Blood and Marrow Transplantation
Norbert-Claude Gorin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A >= 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse
Steven Lane et al.
LEUKEMIA & LYMPHOMA (2008)
The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors
M. Weisser et al.
LEUKEMIA (2007)
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
Frederick R. Appelbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21):: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study
R Cairoli et al.
BLOOD (2006)
Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation
DP Lu et al.
BLOOD (2006)
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
S Schnittger et al.
BLOOD (2006)
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]
G Perea et al.
LEUKEMIA (2006)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16):: A cancer and leukemia group B study
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)
H Leroy et al.
LEUKEMIA (2005)
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia:: A survey of the German Acute Myeloid Leukemia Intergroup
RF Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFB-MYH11+ acute myeloid leukemia based on quantification of fusion transcripts
S Schnittger et al.
BLOOD (2003)
Determination of minimal residual disease in leukaemia patients
D Campana
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias
J Krauter et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML):: a survey of 161 cases from the French AML Intergroup
S Nguyen et al.
BLOOD (2002)
Share Paper
